Epidarex Capital
North America, Maryland, United States, Bethesda
Description
Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and them.
Investor Profile
Epidarex Capital has made 47 investments, with 3 in the past 12 months and 47% as lead.
Stage Focus
- Series A (53%)
- Series B (17%)
- Seed (15%)
- Series Unknown (9%)
- Series E (2%)
- Series C (2%)
- Series D (2%)
Country Focus
- United Kingdom (70%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- United States (21%)
- Germany (9%)
Industry Focus
- Biotechnology
- Therapeutics
- Health Care
- Life Science
- Medical
- Health Diagnostics
- Pharmaceutical
- Oncology
- Biopharma
- Medical Device
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
